publication date: Jul. 20, 2018

In Brief NCI, NIMHD, PCF launch $26.5M study on aggressive prostate cancer in African-American men

 A $26.5 million study will investigate environmental and genetic factors related to aggressiveness of prostate cancer in African-American men to better understand why they disproportionally experience aggressive disease—cancer that grows and spreads quickly—compared with men of other racial and ethnic groups.

The study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress.

RESPOND is supported by NCI and the National Institute on Minority Health and Health Disparities, as well as by the Prostate Cancer Foundation. The NCI funding will be provided from the 21st Century Cures Cancer Moonshot Initiative.

“Understanding why African-American men are more likely to be diagnosed with aggressive prostate cancer than men of other racial and ethnic groups is a critical, unanswered question in cancer disparities research,” said NCI Director Ned Sharpless. “This large, collaborative study can help the cancer research community better understand and address these disparities.”

African-American men have about a 15 percent chance of developing prostate cancer in their lifetimes, compared to about a 10 percent chance for white men, and African-American men are more likely to be diagnosed with aggressive disease. In addition, the risk of dying from … Continue reading NCI, NIMHD, PCF launch $26.5M study on aggressive prostate cancer in African-American men

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.